{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T20:02:58Z","timestamp":1785528178843,"version":"3.56.0"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,6,4]],"date-time":"2021-06-04T00:00:00Z","timestamp":1622764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,4]],"date-time":"2021-06-04T00:00:00Z","timestamp":1622764800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Insights Imaging"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Therapy of uveal melanoma aims to preserve the eye and its function and to avoid metastatic dissemination. The treatment choice is difficult and must keep into account several factors; the therapeutic strategy of uveal melanoma should therefore be personalized, sometimes requiring to combine different treatment techniques. Nowadays globe-sparing radiotherapy techniques are often preferred to enucleation. Plaque brachytherapy, the most commonly used eye-preserving therapy, is suitable for small- and medium-sized uveal melanomas. Proton beam radiotherapy is indicated for tumours with noticeable size, challenging shape and location, but is more expensive and less available than brachytherapy. Enucleation is currently restricted to advanced tumours, uveal melanomas with orbital or optic nerve involvement, blind and painful eyes because of treatment-related complications (neovascular glaucoma, chronic inflammatory processes). The effect of proton beam therapy on neoplastic tissue is related to direct cytotoxic action of the radiations, impairment of neoplastic vascular supply and immunologic response. Complications after radiotherapy are frequent and numerous and mainly related to tumour thickness, radiation dose and distance between the tumour and optic nerve. The purpose of this pictorial review is to provide the radiologists with awareness about diagnostic methods and therapeutic options of uveal melanoma. In the present second section, we discuss the therapeutic management of uveal melanoma, describing the main ocular-conserving radiotherapic techniques. We subsequently present an overview of the effects of radiations on neoplastic tissue. Lastly, we review ocular complications following radiotherapy that should be evaluated by radiologists during follow-up MRI examinations.<\/jats:p>","DOI":"10.1186\/s13244-021-01001-w","type":"journal-article","created":{"date-parts":[[2021,6,4]],"date-time":"2021-06-04T01:05:26Z","timestamp":1622768726000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Diagnostic methods and therapeutic options of uveal melanoma with emphasis on MR imaging\u2014Part II: treatment indications and complications"],"prefix":"10.1186","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0918-0103","authenticated-orcid":false,"given":"Pietro Valerio","family":"Foti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Travali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato","family":"Farina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Palmucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corrado","family":"Spatola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rocco Luca Emanuele","family":"Liardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Milazzotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Raffaele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Salamone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosario","family":"Caltabiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Broggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidia","family":"Puzzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Reibaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Longo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Vigneri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresio","family":"Avitabile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovani Carlo","family":"Ettorre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Basile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,4]]},"reference":[{"key":"1001_CR1","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1159\/000328251","volume":"49","author":"BE Damato","year":"2012","unstructured":"Damato BE (2012) Treatment selection for uveal melanoma. Dev Ophthalmol 49:16\u201326. https:\/\/doi.org\/10.1159\/000328251","journal-title":"Dev Ophthalmol"},{"issue":"3","key":"1001_CR2","doi-asserted-by":"publisher","first-page":"123","DOI":"10.4274\/tjo.37431","volume":"46","author":"B Tarlan","year":"2016","unstructured":"Tarlan B, K\u0131ratl\u0131 H (2016) Uveal melanoma: current trends in diagnosis and management. Turk J Ophthalmol 46(3):123\u2013137. https:\/\/doi.org\/10.4274\/tjo.37431","journal-title":"Turk J Ophthalmol"},{"issue":"3","key":"1001_CR3","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1097\/ICU.0000000000000468","volume":"29","author":"D Reichstein","year":"2018","unstructured":"Reichstein D, Karan K (2018) Plaque brachytherapy for posterior uveal melanoma in 2018: improved techniques and expanded indications. Curr Opin Ophthalmol 29(3):191\u2013198. https:\/\/doi.org\/10.1097\/ICU.0000000000000468","journal-title":"Curr Opin Ophthalmol"},{"issue":"2","key":"1001_CR4","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/eye.2012.249","volume":"27","author":"C Groenewald","year":"2013","unstructured":"Groenewald C, Konstantinidis L, Damato B (2013) Effects of radiotherapy on uveal melanomas and adjacent tissues. Eye 27(2):163\u2013171. https:\/\/doi.org\/10.1038\/eye.2012.249","journal-title":"Eye"},{"issue":"2","key":"1001_CR5","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1111\/j.1442-9071.1993.tb00759.x","volume":"21","author":"Z Qiang","year":"1993","unstructured":"Qiang Z, Cairns JD (1993) Laser photocoagulation treatment of choroidal melanoma. Aust N Z J Ophthalmol 21(2):87\u201392. https:\/\/doi.org\/10.1111\/j.1442-9071.1993.tb00759.x","journal-title":"Aust N Z J Ophthalmol"},{"issue":"1","key":"1001_CR6","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1034\/j.1600-0420.2002.800106.x","volume":"80","author":"BM Stoffelns","year":"2002","unstructured":"Stoffelns BM (2002) Primary transpupillary thermotherapy (TTT) for malignant choroidal melanoma. Acta Ophthalmol Scand 80(1):25\u201331. https:\/\/doi.org\/10.1034\/j.1600-0420.2002.800106.x","journal-title":"Acta Ophthalmol Scand"},{"issue":"4","key":"1001_CR7","doi-asserted-by":"publisher","first-page":"392","DOI":"10.5114\/jcb.2019.87407","volume":"11","author":"KV Peddada","year":"2019","unstructured":"Peddada KV, Sangani R, Menon H, Verma V (2019) Complications and adverse events of plaque brachytherapy for ocular melanoma. J Contemp Brachytherapy 11(4):392\u2013397. https:\/\/doi.org\/10.5114\/jcb.2019.87407","journal-title":"J Contemp Brachytherapy"},{"key":"1001_CR8","doi-asserted-by":"publisher","unstructured":"Collaborative Ocular Melanoma Study Group (2006) The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: V. Twelve-year mortality rates and prognostic factors: COMS report No. 28. Arch Ophthalmol. 124(12):1684\u201393. https:\/\/doi.org\/10.1001\/archopht.124.12.1684.","DOI":"10.1001\/archopht.124.12.1684"},{"issue":"4","key":"1001_CR9","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s40942-018-0123-1","volume":"13","author":"OA Sorour","year":"2018","unstructured":"Sorour OA, Mignano JE, Duker JS (2018) Gamma Knife radiosurgery for locally recurrent choroidal melanoma following plaque radiotherapy. Int J Retina Vitreous 13(4):23. https:\/\/doi.org\/10.1186\/s40942-018-0123-1","journal-title":"Int J Retina Vitreous"},{"issue":"2","key":"1001_CR10","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.radonc.2013.08.004","volume":"108","author":"R Dunavoelgyi","year":"2013","unstructured":"Dunavoelgyi R, Zehetmayer M, Gleiss A, et al (2013) Hypofractionated stereotactic photon radiotherapy of posteriorly located choroidal melanoma with five fractions at ten Gy\u2013clinical results after six years of experience. Radiother Oncol 108(2):342\u2013347. https:\/\/doi.org\/10.1016\/j.radonc.2013.08.004","journal-title":"Radiother Oncol"},{"issue":"2","key":"1001_CR11","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1159\/000501971","volume":"6","author":"GM Modorati","year":"2020","unstructured":"Modorati GM, Dagan R, Mikkelsen LH, Andreasen S, Ferlito A (2020) Gamma knife radiosurgery for uveal melanoma: a retrospective review of clinical complications in a tertiary referral center. Ocul Oncol Pathol 6(2):115\u2013122. https:\/\/doi.org\/10.1159\/000501971","journal-title":"Ocul Oncol Pathol"},{"issue":"1","key":"1001_CR12","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s13014-018-1088-9","volume":"13","author":"S Akbaba","year":"2018","unstructured":"Akbaba S, Foerster R, Nicolay NH, et al (2018) Linear accelerator-based stereotactic fractionated photon radiotherapy as an eye-conserving treatment for uveal melanoma. Radiat Oncol 13(1):140. https:\/\/doi.org\/10.1186\/s13014-018-1088-9","journal-title":"Radiat Oncol"},{"issue":"2","key":"1001_CR13","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.jnci.2016.02.003","volume":"28","author":"A Kapoor","year":"2016","unstructured":"Kapoor A, Beniwal V, Beniwal S, Mathur H, Kumar HS (2016) Management of uveal tract melanoma: a comprehensive review. J Egypt Natl Canc Inst 28(2):65\u201372. https:\/\/doi.org\/10.1016\/j.jnci.2016.02.003","journal-title":"J Egypt Natl Canc Inst"},{"issue":"1","key":"1001_CR14","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41572-020-0158-0","volume":"6","author":"MJ Jager","year":"2020","unstructured":"Jager MJ, Shields CL, Cebulla CM, et al (2020) Uveal melanoma. Nat Rev Dis Primers 6(1):24. https:\/\/doi.org\/10.1038\/s41572-020-0158-0","journal-title":"Nat Rev Dis Primers"},{"issue":"3","key":"1001_CR15","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.ophtha.2014.09.029","volume":"122","author":"A Mashayekhi","year":"2015","unstructured":"Mashayekhi A, Shields CL, Rishi P, et al (2015) Primary transpupillary thermotherapy for choroidal melanoma in 391 cases: importance of risk factors in tumor control. Ophthalmology 122(3):600\u2013609. https:\/\/doi.org\/10.1016\/j.ophtha.2014.09.029","journal-title":"Ophthalmology"},{"key":"1001_CR16","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.2147\/OPTH.S238405","volume":"14","author":"L Grech Fonk","year":"2020","unstructured":"Grech Fonk L, Ferreira TA, Webb AG, Luyten GPM, Beenakker JM (2020) The economic value of MR-imaging for uveal melanoma. Clin Ophthalmol 14:1135\u20131143. https:\/\/doi.org\/10.2147\/OPTH.S238405","journal-title":"Clin Ophthalmol"},{"issue":"4","key":"1001_CR17","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1097\/IAE.0000000000001585","volume":"38","author":"A Russo","year":"2018","unstructured":"Russo A, Reibaldi M, Avitabile T, et al (2018) Dexamethasone intravitreal implant vs ranibizumab in the treatment of macular edema secondary to brachytherapy for choroidal melanoma. Retina 38(4):788\u2013794. https:\/\/doi.org\/10.1097\/IAE.0000000000001585","journal-title":"Retina"},{"issue":"7","key":"1001_CR18","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1007\/s00417-019-04347-6","volume":"257","author":"M Fallico","year":"2019","unstructured":"Fallico M, Reibaldi M, Avitabile T, et al (2019) Intravitreal aflibercept for the treatment of radiation-induced macular edema after ruthenium 106 plaque radiotherapy for choroidal melanoma. Graefes Arch Clin Exp Ophthalmol 257(7):1547\u20131554. https:\/\/doi.org\/10.1007\/s00417-019-04347-6","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1001_CR19","doi-asserted-by":"publisher","unstructured":"Hawkins BS; Collaborative Ocular Melanoma Study Group (2004) The Collaborative Ocular Melanoma Study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma: IV. Ten-year mortality findings and prognostic factors. COMS report number 24. Am J Ophthalmol. 138(6):936\u201351. https:\/\/doi.org\/10.1016\/j.ajo.2004.07.006.","DOI":"10.1016\/j.ajo.2004.07.006"},{"key":"1001_CR20","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1016\/s0360-3016(03)00324-9","volume":"56","author":"S Nag","year":"2003","unstructured":"Nag S, Wang D, Wu H, Bauer CJ, Chambers RB (2003) Custom-made \u2018Nag\u2019 eye plaques for 125I brachytherapy. Int J Radiat Oncol Biol Phys 56:1373\u20131380. https:\/\/doi.org\/10.1016\/s0360-3016(03)00324-9","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1001_CR21","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1007\/s13246-016-0480-8","volume":"39","author":"L Sim","year":"2016","unstructured":"Sim L (2016) Novel application of 3D printing in brachytherapy using MED610 3D printed insert for I-125 ROPES eye plaque. Aust Phys Eng Sci Med 39:863\u2013870. https:\/\/doi.org\/10.1007\/s13246-016-0480-8","journal-title":"Aust Phys Eng Sci Med"},{"key":"1001_CR22","doi-asserted-by":"publisher","first-page":"49","DOI":"10.2147\/OPTH.S3555","volume":"3","author":"S Aziz","year":"2009","unstructured":"Aziz S, Taylor A, McConnachie A, Kacperek A, Kemp E (2009) Proton beam radiotherapy in the management of uveal melanoma: Clinical experience in Scotland. Clin Ophthalmol 3:49\u201355. https:\/\/doi.org\/10.2147\/OPTH.S3555","journal-title":"Clin Ophthalmol"},{"key":"1001_CR23","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1159\/000328257","volume":"49","author":"L Desjardins","year":"2012","unstructured":"Desjardins L, Lumbroso-Le Rouic L, Levy-Gabriel C, et al (2012) Treatment of uveal melanoma by accelerated proton beam. Dev Ophthalmol 49:41\u201357. https:\/\/doi.org\/10.1159\/000328257","journal-title":"Dev Ophthalmol"},{"key":"1001_CR24","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/0002-9394(77)90133-7","volume":"83","author":"ES Gragoudas","year":"1977","unstructured":"Gragoudas ES, Goitein M, Koehler AM, et al (1977) Proton irradiation of small choroidal malignant melanomas. Am J Ophthalmol 83:665\u2013673. https:\/\/doi.org\/10.1016\/0002-9394(77)90133-7","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"1001_CR25","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.sjopt.2013.06.014","volume":"27","author":"B Damato","year":"2013","unstructured":"Damato B, Kacperek A, Errington D, Heimann H (2013) Proton beam radiotherapy of uveal melanoma. Saudi J Ophthalmol 27(3):151\u2013157. https:\/\/doi.org\/10.1016\/j.sjopt.2013.06.014","journal-title":"Saudi J Ophthalmol"},{"key":"1001_CR26","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1140\/epjp\/i2011-11065-1","volume":"126","author":"G Cuttone","year":"2011","unstructured":"Cuttone G, Cirrone GAP, Di Franco G, et al (2011) CATANA protontherapy facility: the state of art of clinical and dosimetric experience. Eur Phys J Plus 126:65. https:\/\/doi.org\/10.1140\/epjp\/i2011-11065-1","journal-title":"Eur Phys J Plus"},{"key":"1001_CR27","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1063\/1.4816618","volume":"1546","author":"C Spatola","year":"2013","unstructured":"Spatola C, Privitera G (2013) Clinical aspects and potential clinical applications of laser accelerated proton beams. AIP Conf Proc 1546:108\u2013111. https:\/\/doi.org\/10.1063\/1.4816618","journal-title":"AIP Conf Proc"},{"key":"1001_CR28","doi-asserted-by":"publisher","first-page":"223","DOI":"10.3389\/fonc.2017.00223","volume":"7","author":"GAP Cirrone","year":"2017","unstructured":"Cirrone GAP, Cuttone G, Raffaele L, et al (2017) Clinical and research activities at the CATANA facility of INFN-LNS: from the conventional hadrontherapy to the laser-driven approach. Front Oncol 7:223. https:\/\/doi.org\/10.3389\/fonc.2017.00223","journal-title":"Front Oncol"},{"issue":"4","key":"1001_CR29","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.ajo.2015.06.017","volume":"160","author":"I Seibel","year":"2015","unstructured":"Seibel I, Cordini D, Rehak M, et al (2015) Local recurrence after primary proton beam therapy in uveal melanoma: risk factors, retreatment approaches, and outcome. Am J Ophthalmol 160(4):628\u2013636. https:\/\/doi.org\/10.1016\/j.ajo.2015.06.017","journal-title":"Am J Ophthalmol"},{"issue":"11","key":"1001_CR30","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1136\/bjo.85.11.1305","volume":"85","author":"L Lumbroso","year":"2001","unstructured":"Lumbroso L, Desjardins L, Levy C, et al (2001) Intraocular inflammation after proton beam irradiation for uveal melanoma. Br J Ophthalmol 85(11):1305\u20131308. https:\/\/doi.org\/10.1136\/bjo.85.11.1305","journal-title":"Br J Ophthalmol"},{"key":"1001_CR31","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1016\/S0161-6420(81)34883-0","volume":"88","author":"KM Zinn","year":"1981","unstructured":"Zinn KM, Stein PK, Jakobiec FA, Friedman AH, Gragoudas ES, Ritch R (1981) Proton-beam irradiated epithelioid cell melanoma of the ciliary body. Ophthalmology 88:1315\u20131321. https:\/\/doi.org\/10.1016\/S0161-6420(81)34883-0","journal-title":"Ophthalmology"},{"key":"1001_CR32","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1001\/archopht.1985.01050120083027","volume":"103","author":"AP Ferry","year":"1985","unstructured":"Ferry AP, Blair CJ, Gragoudas ES, Volk SC (1985) Pathologic examination of ciliary body melanoma treated with proton beam irradiation. Arch Ophthalmol 103:1849\u20131853. https:\/\/doi.org\/10.1001\/archopht.1985.01050120083027","journal-title":"Arch Ophthalmol"},{"issue":"3","key":"1001_CR33","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s10334-016-0529-4","volume":"29","author":"J-WM Beenakker","year":"2016","unstructured":"Beenakker J-WM, Ferreira TA, Soemarwoto KP, et al (2016) Clinical evaluation of ultra-high-field MRI for three-dimensional visualisation of tumour size in uveal melanoma patients, with direct relevance to treatment planning. MAGMA 29(3):571\u2013577. https:\/\/doi.org\/10.1007\/s10334-016-0529-4","journal-title":"MAGMA"},{"issue":"6","key":"1001_CR34","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1038\/eye.2009.43","volume":"23","author":"JC Wen","year":"2009","unstructured":"Wen JC, Oliver SC, McCannel TA (2009) Ocular complications following I-125 brachytherapy for choroidal melanoma. Eye 23(6):1254\u20131268. https:\/\/doi.org\/10.1038\/eye.2009.43","journal-title":"Eye"},{"key":"1001_CR35","doi-asserted-by":"publisher","first-page":"169","DOI":"10.4236\/jct.2016.73018","volume":"7","author":"V Tseng","year":"2016","unstructured":"Tseng V, Coleman A, Zhang Z, McCannel T (2016) Complications from plaque versus proton beam therapy for choroidal melanoma: a qualitative systematic review. J Canc Ther 7:169\u2013185. https:\/\/doi.org\/10.4236\/jct.2016.73018","journal-title":"J Canc Ther"},{"key":"1001_CR36","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.ejca.2016.09.009","volume":"68","author":"M Marinkovic","year":"2016","unstructured":"Marinkovic M, Horeweg N, Fiocco M, et al (2016) Ruthenium-106 brachytherapy for choroidal melanoma without transpupillary thermotherapy: similar efficacy with improved visual outcome. Eur J Cancer 68:106\u2013113. https:\/\/doi.org\/10.1016\/j.ejca.2016.09.009","journal-title":"Eur J Cancer"},{"key":"1001_CR37","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1097\/IAE.0000000000000379","volume":"35","author":"J Garcia-Arumi","year":"2015","unstructured":"Garcia-Arumi J, Leila M, Zapata MA, et al (2015) Endoresection technique with\/ without brachytherapy for management of high posterior choroidal melanoma: extended follow-up results. Retina 35:628\u2013637. https:\/\/doi.org\/10.1097\/IAE.0000000000000379","journal-title":"Retina"},{"issue":"2","key":"1001_CR38","first-page":"185","volume":"5","author":"CP Tataru","year":"2012","unstructured":"Tataru CP, Pop MD (2012) Enucleation in malignant choroidal melanoma: results in 15 years of using a new material in the prosthesis of the orbital cavity. J Med Life 5(2):185\u2013188","journal-title":"J Med Life"},{"issue":"2","key":"1001_CR39","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1001\/archophthalmol.2007.50","volume":"126","author":"RB Avery","year":"2008","unstructured":"Avery RB, Diener-West M, Reynolds SM, Grossniklaus HE, Green WR, Albert DM (2008) Histopathologic characteristics of choroidal melanoma in eyes enucleated after iodine 125 brachytherapy in the collaborative ocular melanoma study. Arch Ophthalmol 126(2):207\u2013212. https:\/\/doi.org\/10.1001\/archophthalmol.2007.50","journal-title":"Arch Ophthalmol"},{"issue":"10","key":"1001_CR40","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.1007\/s00417-019-04413-z","volume":"257","author":"A Hager","year":"2015","unstructured":"Hager A, Meissner F, Riechardt AI, et al (2015) Breakdown of the blood-eye barrier in choroidal melanoma after proton beam radiotherapy. Graefes Arch Clin Exp Ophthalmol 257(10):2323\u20132328. https:\/\/doi.org\/10.1007\/s00417-019-04413-z","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1001_CR41","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1001\/archopht.1983.01040020404014","volume":"101","author":"JM Seddon","year":"1983","unstructured":"Seddon JM, Gragouda ES, Albert DM (1983) Ciliary body and choroidal melanomas treated by proton beam irradiation: histopathologic study of eyes. Arch Ophthalmol 101:1402\u20131408. https:\/\/doi.org\/10.1001\/archopht.1983.01040020404014","journal-title":"Arch Ophthalmol"},{"key":"1001_CR42","doi-asserted-by":"publisher","unstructured":"Kincaid MC, Folberg R, Torczynski E, et al (1988) Complications after proton beam therapy for uveal malignant melanoma. A clinical and histopathologic study of five cases. Ophthalmology. 95(7):982\u201391. https:\/\/doi.org\/10.1016\/s0161-6420(88)33092-7.","DOI":"10.1016\/s0161-6420(88)33092-7"},{"key":"1001_CR43","doi-asserted-by":"crossref","unstructured":"Font RL, Croxatto JO, Rao NA (2006) Tumors of the Eye and Ocular Adnexa. Afip Atlas of Tumor Pathology Series 4. Amer Registry of Pathology, Washington DC.","DOI":"10.55418\/1881041999"},{"issue":"10","key":"1001_CR44","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1016\/s0161-6420(93)31445-4","volume":"100","author":"ES Gragoudas","year":"1993","unstructured":"Gragoudas ES, Egan KM, Saornil MA, Walsh SM, Albert DM, Seddon JM (1993) The time course of irradiation changes in proton beam-treated uveal melanomas. Ophthalmology 100(10):1555\u20131560. https:\/\/doi.org\/10.1016\/s0161-6420(93)31445-4","journal-title":"Ophthalmology"},{"issue":"7","key":"1001_CR45","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1016\/s0161-6420(82)34731-4","volume":"89","author":"SR Wilkes","year":"1982","unstructured":"Wilkes SR, Gragoudas ES (1982) Regression patterns of uveal melanomas after proton beam irradiation. Ophthalmology 89(7):840\u2013844. https:\/\/doi.org\/10.1016\/s0161-6420(82)34731-4","journal-title":"Ophthalmology"},{"issue":"6","key":"1001_CR46","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1007\/s11547-014-0488-7","volume":"120","author":"PV Foti","year":"2015","unstructured":"Foti PV, Farina R, Coronella M, et al (2015) Diffusion-weighted magnetic resonance imaging for predicting and detecting the response of ocular melanoma to proton beam therapy: initial results. Radiol Med 120(6):526\u2013535. https:\/\/doi.org\/10.1007\/s11547-014-0488-7","journal-title":"Radiol Med"},{"issue":"2","key":"1001_CR47","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s11547-016-0697-3","volume":"122","author":"PV Foti","year":"2017","unstructured":"Foti PV, Longo A, Reibaldi M, et al (2017) Uveal melanoma: quantitative evaluation of diffusion-weighted MR imaging in the response assessment after proton-beam therapy, long-term follow-up. Radiol Med 122(2):131\u2013139. https:\/\/doi.org\/10.1007\/s11547-016-0697-3","journal-title":"Radiol Med"},{"issue":"7","key":"1001_CR48","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1136\/bjo.2003.036285","volume":"88","author":"I Kaiserman","year":"2004","unstructured":"Kaiserman I, Anteby I, Chowers I, Blumenthal EZ, Kliers I, Pe\u2019er J (2004) Post-brachytherapy initial tumour regression rate correlates with metastatic spread in posterior uveal melanoma. Br J Ophthalmol 88(7):892\u2013895. https:\/\/doi.org\/10.1136\/bjo.2003.036285","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"1001_CR49","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/s1016-3190(08)60004-x","volume":"20","author":"M-S Chen","year":"2008","unstructured":"Chen M-S, Hou P-K, Tai T-Y, Lin BJ (2008) Blood-ocular barriers. Tzu Chi Med J 20(1):25\u201334. https:\/\/doi.org\/10.1016\/s1016-3190(08)60004-x","journal-title":"Tzu Chi Med J"},{"issue":"1","key":"1001_CR50","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.nic.2005.02.005","volume":"15","author":"MF Mafee","year":"2005","unstructured":"Mafee MF, Karimi A, Shah J, Rapoport M, Ansari SA (2005) Anatomy and pathology of the eye: role of MR imaging and CT. Neuroimaging Clin N Am 15(1):23\u201347. https:\/\/doi.org\/10.1016\/j.nic.2005.02.005","journal-title":"Neuroimaging Clin N Am"},{"issue":"16","key":"1001_CR51","doi-asserted-by":"publisher","first-page":"e120","DOI":"10.3346\/jkms.2018.33.e120","volume":"33","author":"YJ Choi","year":"2018","unstructured":"Choi YJ, Kim TW, Kim S, et al (2018) Effects on periocular tissues after proton beam radiation therapy for intraocular tumors. J Korean Med Sci 33(16):e120. https:\/\/doi.org\/10.3346\/jkms.2018.33.e120","journal-title":"J Korean Med Sci"},{"issue":"2","key":"1001_CR52","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/eye.2012.242","volume":"27","author":"B Damato","year":"2013","unstructured":"Damato B, Heimann H (2013) Personalized treatment of uveal melanoma. Eye 27(2):172\u2013179. https:\/\/doi.org\/10.1038\/eye.2012.242","journal-title":"Eye"},{"key":"1001_CR53","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.ajo.2016.02.027","volume":"165","author":"E Bensoussan","year":"2016","unstructured":"Bensoussan E, Thariat J, Maschi C, et al (2016) Outcomes after proton beam therapy for large choroidal melanomas in 492 patients. Am J Ophthalmol 165:78\u201387. https:\/\/doi.org\/10.1016\/j.ajo.2016.02.027","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"1001_CR54","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1080\/01676830.2017.1337183","volume":"36","author":"CM Pham","year":"2017","unstructured":"Pham CM, Custer PL, Couch SM (2017) Comparison of primary and secondary enucleation for uveal melanoma. Orbit 36(6):422\u2013427. https:\/\/doi.org\/10.1080\/01676830.2017.1337183","journal-title":"Orbit"},{"issue":"4","key":"1001_CR55","doi-asserted-by":"publisher","first-page":"273","DOI":"10.3109\/09273948.2012.689072","volume":"20","author":"J Brour","year":"2012","unstructured":"Brour J, Desjardins L, Lehoang P, et al (2012) Sympathetic ophthalmia after proton beam irradiation for choro\u00efdal melanoma. Ocul Immunol Inflamm 20(4):273\u2013276. https:\/\/doi.org\/10.3109\/09273948.2012.689072","journal-title":"Ocul Immunol Inflamm"},{"issue":"2","key":"1001_CR56","doi-asserted-by":"publisher","first-page":"186","DOI":"10.22608\/APO.201734","volume":"6","author":"M Dogrus\u00f6z","year":"2017","unstructured":"Dogrus\u00f6z M, Jager MJ, Damato B (2017) Uveal melanoma treatment and prognostication. Asia Pac J Ophthalmol 6(2):186\u2013196. https:\/\/doi.org\/10.22608\/APO.201734","journal-title":"Asia Pac J Ophthalmol"},{"issue":"4","key":"1001_CR57","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1111\/aos.13580","volume":"96","author":"M Dogrus\u00f6z","year":"2018","unstructured":"Dogrus\u00f6z M, Jager MJ (2018) Genetic prognostication in uveal melanoma. Acta Ophthalmol 96(4):331\u2013347. https:\/\/doi.org\/10.1111\/aos.13580","journal-title":"Acta Ophthalmol"},{"key":"1001_CR58","doi-asserted-by":"publisher","first-page":"147","DOI":"10.2147\/TACG.S69210","volume":"9","author":"H Helgadottir","year":"2016","unstructured":"Helgadottir H, H\u00f6iom V (2016) The genetics of uveal melanoma: current insights. Appl Clin Genet 9:147\u2013155. https:\/\/doi.org\/10.2147\/TACG.S69210","journal-title":"Appl Clin Genet"},{"key":"1001_CR59","doi-asserted-by":"publisher","unstructured":"Agarwala SS, Eggermont AM, O'Day S, Zager JS (2014) Metastatic melanoma to the liver: a contemporary and comprehensive review of surgical, systemic, and regional therapeutic options. Cancer. 15;120(6):781\u20139. https:\/\/doi.org\/10.1002\/cncr.28480.","DOI":"10.1002\/cncr.28480"},{"issue":"1","key":"1001_CR60","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1136\/bjophthalmol-2016-309034","volume":"101","author":"RD Carvajal","year":"2017","unstructured":"Carvajal RD, Schwartz GK, Tezel T, Marr B, Francis JH, Nathan PD (2017) Metastatic disease from uveal melanoma: treatment options and future prospects. Br J Ophthalmol 101(1):38\u201344. https:\/\/doi.org\/10.1136\/bjophthalmol-2016-309034","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"1001_CR61","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1148\/radiol.2019190199","volume":"293","author":"CF Gonsalves","year":"2019","unstructured":"Gonsalves CF, Eschelman DJ, Adamo RD, et al (2019) A prospective phase II trial of radioembolization for treatment of uveal melanoma hepatic metastasis. Radiology 293(1):223\u2013231. https:\/\/doi.org\/10.1148\/radiol.2019190199","journal-title":"Radiology"},{"issue":"1","key":"1001_CR62","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s40487-018-0056-8","volume":"6","author":"M Singh","year":"2018","unstructured":"Singh M, Durairaj P, Yeung J (2018) Uveal melanoma: a review of the literature. Oncol Ther 6(1):87\u2013104. https:\/\/doi.org\/10.1007\/s40487-018-0056-8","journal-title":"Oncol Ther"},{"key":"1001_CR63","doi-asserted-by":"publisher","unstructured":"Mallone F, Sacchetti M, Lambiase A, Moramarco A (2020) Molecular insights and emerging strategies for treatment of metastatic uveal melanoma. Cancers (Basel). 25;12(10):2761. https:\/\/doi.org\/10.3390\/cancers12102761.","DOI":"10.3390\/cancers12102761"},{"issue":"1","key":"1001_CR64","doi-asserted-by":"publisher","first-page":"99","DOI":"10.2214\/AJR.07.2675","volume":"190","author":"KV Sharma","year":"2008","unstructured":"Sharma KV, Gould JE, Harbour JW, et al (2008) Hepatic arterial chemoembolization for management of metastatic melanoma. AJR Am J Roentgenol 190(1):99\u2013104. https:\/\/doi.org\/10.2214\/AJR.07.2675","journal-title":"AJR Am J Roentgenol"},{"issue":"9","key":"1001_CR65","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.3390\/cancers12092557","volume":"12","author":"C Rodriguez-Vidal","year":"2020","unstructured":"Rodriguez-Vidal C, Fernandez-Diaz D, Fernandez-Marta B, et al (2020) Treatment of metastatic uveal melanoma: systematic review. Cancers (Basel) 12(9):2557. https:\/\/doi.org\/10.3390\/cancers12092557","journal-title":"Cancers (Basel)"},{"issue":"2","key":"1001_CR66","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1245\/s10434-013-3304-z","volume":"21","author":"R Olofsson","year":"2014","unstructured":"Olofsson R, Cahlin C, All-Ericsson C, et al (2014) Isolated hepatic perfusion for ocular melanoma metastasis: registry data suggests a survival benefit. Ann Surg Oncol 21(2):466\u2013472. https:\/\/doi.org\/10.1245\/s10434-013-3304-z","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"1001_CR67","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s40644-019-0218-4","volume":"19","author":"C Artzner","year":"2019","unstructured":"Artzner C, Mossakowski O, Hefferman G, et al (2019) Chemosaturation with percutaneous hepatic perfusion of melphalan for liver-dominant metastatic uveal melanoma: a single center experience. Cancer Imaging 19(1):31. https:\/\/doi.org\/10.1186\/s40644-019-0218-4","journal-title":"Cancer Imaging"},{"issue":"1","key":"1001_CR68","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1007\/s00270-012-0373-5","volume":"36","author":"A Klingenstein","year":"2013","unstructured":"Klingenstein A, Haug AR, Zech CJ, Schaller UC (2013) Radioembolization as locoregional therapy of hepatic metastases in uveal melanoma patients. Cardiovasc Intervent Radiol 36(1):158\u2013165. https:\/\/doi.org\/10.1007\/s00270-012-0373-5","journal-title":"Cardiovasc Intervent Radiol"}],"container-title":["Insights into Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13244-021-01001-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13244-021-01001-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13244-021-01001-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,29]],"date-time":"2022-12-29T18:57:00Z","timestamp":1672340220000},"score":1,"resource":{"primary":{"URL":"https:\/\/insightsimaging.springeropen.com\/articles\/10.1186\/s13244-021-01001-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,4]]},"references-count":68,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1001"],"URL":"https:\/\/doi.org\/10.1186\/s13244-021-01001-w","relation":{},"ISSN":["1869-4101"],"issn-type":[{"value":"1869-4101","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,4]]},"assertion":[{"value":"23 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests in the manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"67"}}